Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Fructooligosaccharides vs Galactooligosaccharides: Galactooligosaccharides has the stronger overall evidence (5 vs 4.5/10); they're alternatives for improve digestion — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Galactooligosaccharides wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Likely helps
4 of 4 studies with measurable effects showed benefit.
Top outcomes
Verdict
Probably helps
2 of 4 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (1)
Outcomes where both Fructooligosaccharides and Galactooligosaccharides have evidence — compare verdict strength side-by-side.
5-10 g/day. The meta-analysis found larger bifidogenic effects above 5 g/d, and the dose-finding study concluded 10 g/d was the optimal well-tolerated dose. Do not extrapolate upward: at 20 g/d excess flatus became significantly more frequent and more intense
Split across two servings with meals, Any time of day — no trial compared timings
Short-chain FOS (scFOS) powder
3.5-5.5 g/day. Going higher is not supported: in the one IBS trial, 3.5 g/d improved more symptoms than 7 g/d, and in stressed students 2.5 g lowered cold-or-flu symptom scores across all stress levels while 5 g helped only at lower stress
With meals, Split across two servings if a single dose causes gas
Trans-galactooligosaccharide (B-GOS) powder, the form used in the trials
Combining them roughly doubles the fermentable load without adding a distinct mechanism. Additive flatulence and bloating. No trial has tested the combination.
Pick one. If you take both, start well below the sum of the two individual doses — and note that in the GOS dose comparisons the LOWER dose performed better on symptoms.
1-2 weeks
4 weeks
n/a
n/a
1-2 weeks
8 weeks
n/a
n/a
Effect of Fructooligosaccharides Supplementation on the Gut Microbiota in Human: A Systematic Review and Meta-Analysis.
Nutrients (2022) · Meta analysis · n=388
Bifidobacterium spp. counts increased significantly with FOS (WMD 0.579; 95% CI 0.444-0.714) versus control
The capacity of nondigestible carbohydrates to stimulate fecal bifidobacteria in healthy humans: a double-blind, randomized, placebo-controlled, parallel-group, dose-response relation study.
Am J Clin Nutr (2004) · Rct · n=64
Sample size recorded as 64 — the phase-1 head-to-head randomised 64 volunteers into 8 groups of 8. The study enrolled 200 in total, but the other 136 were in a phase-2 dose-response restricted to carbohydrates already shown bifidogenic, so long-chain inulin was never tested beyond n=8.
Short-chain fructo-oligosaccharide administration dose-dependently increases fecal bifidobacteria in healthy humans.
J Nutr (1999) · Rct · n=40
40 healthy volunteers randomised to 0, 2.5, 5, 10 or 20 g/d of short-chain FOS for 7 days, given in two oral doses
Prebiotics in irritable bowel syndrome and other functional bowel disorders in adults: a systematic review and meta-analysis of randomized controlled trials.
Am J Clin Nutr (2019) · Meta analysis · n=729
Global response was NULL: 52/97 (54%) responded on prebiotic versus 59/94 (63%) on placebo (OR 0.62; 95% CI 0.07, 5.69; P=0.67)
Dietary fiber intervention on gut microbiota composition in healthy adults: a systematic review and meta-analysis.
Am J Clin Nutr (2018) · Meta analysis · n=2099
Fibre raised Bifidobacterium spp. overall (SMD 0.64; 95% CI 0.42, 0.86; P<0.00001) and Lactobacillus spp. (SMD 0.22; 0.03, 0.41; P=0.02)
Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome.
Aliment Pharmacol Ther (2009) · Rct · n=44
44 patients with Rome II positive IBS completed a 12-week single-centre trial of 3.5 g/d prebiotic, 7 g/d prebiotic, or 7 g/d placebo
Galactooligosaccharides has a higher evidence score (5/10 vs 4.5/10) and wins in 2 of 3 categories.
For improve digestion, Galactooligosaccharides has a higher relevance score (40 vs 35).
Combining them roughly doubles the fermentable load without adding a distinct mechanism. Additive flatulence and bloating. No trial has tested the combination. Pick one. If you take both, start well below the sum of the two individual doses — and note that in the GOS dose comparisons the LOWER dose performed better on symptoms. Consult a healthcare provider for personalized advice.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.